Report Overview

The global lung cancer screening market was pegged at US$ 2.65 billion in 2021 and is expected to witness a CAGR of 7.7% during the forecast period

Market Fundamentals 

Lung cancer also known as lung carcinoma, is the most common cancer across the globe. It is characterized by the uncontrolled growth of cells in the lung tissues. There are two types of lung cancer namely, small cell lung carcinoma and non-small cell lung carcinoma. The common symptoms associated are coughing, chest pain, shortness of breath, and weight loss. Lung cancer screening is done for the early detection of cancer, in a healthy population as a preventive measure. Screening tests for lung cancer include imaging, biomarkers test, and biopsy. 

Market Dynamics

[345343]

The global lung cancer screening market is flourishing due to the increasing prevalence of lung cancer cases due to increasing consumption of tobacco, exposure to toxic fumes such as radon, asbestos, and air pollution. Additionally, the introduction of technological advancements in the areas of precision, cost-effectiveness, and accuracy; rising awareness levels among the population, and the availability of private & public funds for R&D to develop better cancer diagnostic tools are anticipated to contribute to the global lung cancer screening market growth. Also, market players’ growing adoption of inorganic expansion tactics like acquisitions and collaborations further boosts the market size. 

However, the high price of diagnostic imaging equipment is anticipated to restrain market expansion. Additionally, it is anticipated that the market for lung cancer screening would face challenges in the next years due to the development of numerous diagnostic methods for various cancer mutations.

Market Ecosystem

The global lung cancer screening market has been analyzed from three perspectives: cancer type, test type, end-user, and region. 

Lung Cancer Screening Market by Cancer Type

The global lung cancer screening market has been subdivided into two types: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer holds most of the market share because it is the most common type of cancer. The increasing awareness of screening in both the developed and developing economies along with the increasing cases of NSCLC are the factors responsible for this dominance.

Lung Cancer Screening Market by Test Type

[635322]

Based on test type, the global lung cancer screening market is segmented into biopsy, imaging, and biomarker test. The biopsy is further divided into needle biopsy, open biopsy, and bronchoscopy biopsy. Imaging tests are further divided into CT scan, PET scan, chest X-rays, and others, whereas biomarker testing is further divided into HER2 tests, KER mutation tests, EGFR mutation tests, ALK tests, etc. The CT scan or computed tomography especially the low-dose CT dominates the lung cancer screening market. This is attributed to the favorable reimbursements and growing adoption of low-dose CT scans for lung cancer screening. Additionally, the mortality benefits associated with the use of low-dose CT scan is also favoring the market growth. 

The forecast period would be witnessing a high growth rate of biomarker testing due to the extensive research and development of new cancer biomarkers and assays. 

Lung Cancer Screening Market by End-User

Based on end-user, the global lung cancer screening market is segmented into, cancer research institutes, diagnostic imaging centers, hospital-associated labs, and independent diagnostic laboratories. The hospital-associated labs hold most of the market share due to high patient footfall in hospitals for cancer screening and the existence of more advanced screening equipment due to high investments made by this segment. The diagnostic imaging centers segment is expected to witness a high CAGR in the forecast period due to the increasing number of diagnostic centers globally and the growing spending capacity of payers and the providers. 

Lung Cancer Screening Market by Region  

The global lung cancer screening market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World, based on region. The lung cancer screening market is largely dominated by North America. The high market penetration rates of technologically improved products, the growing patient awareness, and the rising smoking incidence in the area are all cited as contributing factors. Additionally, a favorable reimbursement structure (particularly after the passage of the Affordable Care Act) and an advanced healthcare system are anticipated to increase the use of diagnostics instruments in North America. The expansion of the regional market is anticipated to be further boosted by initiatives like the American Lung Association's (ALA) smoking cessation programs and campaigns to raise awareness of the signs of lung cancer.

In addition, the introduction of novel lung cancer diagnostic and screening tools is anticipated to significantly boost the Asia Pacific lung cancer diagnostic and screening market.

Competitive Landscape

Some of the prominent players operating in the global lung cancer screening market are:

• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Sanofi S.A.
• Agilent Technologies
• Roche Diagnostics
• FUJIFILM Holdings Corporation
• Medtronic plc.
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthineers AG
• Koninklije Philips N.V.

Strategic Developments

• In May 2021. Qiagen NV announced its collaboration with Mirati therapeutics to develop a tissue based KRAS companion diagnostic test to identify non-small cell lung cancer, that may benefit patients to be treated by adagrasib, a KRAS inhibitor. 

Frequently Asked Questions About This Report